SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Therapeutic Advances in Respiratory Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sin, D. D.
Right arrow Articles by Man, S.F. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sin, D. D.
Right arrow Articles by Man, S.F. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Reviews

Review: Surfactant protein D: A lung specific biomarker in COPD?

Don D. Sin

The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, St Paul's Hospital, Room 368A, 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada, dsin{at}mrl.ubc.ca

Payam S. Pahlavan

The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, St Paul's Hospital, Room 368A, 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada

S.F. Paul Man

The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, St Paul's Hospital, Room 368A, 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada

A major impediment in the development of novel drugs for chronic obstructive pulmonary disease (COPD) has been the scarcity of a well-validated, robust, and easily obtainable intermediate end point such as serum biomarkers. To date the best serum biomarkers in COPD have been non-speci"c pro-in"ammatory molecules synthesized largely by extra-pulmonary organs. In COPD, an ideal biomarker would be one that (1) was produced mostly in the lungs (and was reliably measurable in the peripheral circulation using commercially available kits), (2) changed with the clinical status of patients or with relevant exposures; and (3) had inherent functional attributes that suggested a possible causal role in the pathogenesis of the disease. In this paper, we review one promising systemic biomarker that ful"lls some of these criteria, surfactant protein D (SPD).

Key Words: Surfactant D • COPD • biomarker • pathogenesis

Therapeutic Advances in Respiratory Disease, Vol. 2, No. 2, 65-74 (2008)
DOI: 10.1177/1753465808088903
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
D. D. Sin and S. F. Paul Man
Systemic Inflammation and Inhaled Corticosteroids in COPD
Am. J. Respir. Crit. Care Med., January 15, 2009; 179(2): 170 - 171.
[Full Text] [PDF]


Advertisement